{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:48:45Z","timestamp":1790423325137,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004392","name":"Fidelity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Hypokalaemia is associated with cardiovascular events and mortality in patients with chronic kidney disease (CKD). This exploratory FIDELITY analysis, a prespecified pooled patient-dataset from FIDELIO-DKD and FIGARO-DKD, investigated the incidence and effect of hypokalaemia in patients with CKD and type 2 diabetes (T2D) treated with finerenone vs. placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Outcomes include the incidence of treatment-emergent hypokalaemia (serum potassium\u00a0&amp;lt;4.0 or\u00a0&amp;lt;3.5\u00a0mmol\/L) and the effect of finerenone on cardiovascular composite outcome (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure) and arrhythmia composite outcome (new diagnosis of atrial fibrillation\/atrial flutter, hospitalization due to arrhythmia, or sudden cardiac death) by baseline serum potassium subgroups. In the FIDELITY population, treatment-emergent hypokalaemia with serum potassium\u00a0&amp;lt;4.0 and\u00a0&amp;lt;3.5\u00a0mmol\/L occurred in 41.1% and 7.5%, respectively. Hazards of cardiovascular and arrhythmia composite outcomes were higher in patients with baseline serum potassium\u00a0&amp;lt;4.0\u00a0vs. 4.0\u20134.5\u00a0mmol\/L [hazard ratio (HR) 1.16; 95% confidence interval (CI) 1.02\u20131.32, P\u00a0=\u00a00.022 and HR 1.20; 95% CI 1.00\u20131.44, P\u00a0=\u00a00.055, respectively]. Finerenone reduced the incidence of hypokalaemia with serum potassium\u00a0&amp;lt;4.0\u00a0mmol\/L (HR 0.63; 95% CI 0.60\u20130.66) and\u00a0&amp;lt;3.5\u00a0mmol\/L (HR 0.46; 95% CI 0.40\u20130.53) vs. placebo. Finerenone lessened the hazard of cardiovascular and arrhythmia events vs. placebo, irrespective of baseline serum potassium.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A substantial proportion of patients with CKD and T2D experienced hypokalaemia, which was associated with an increased hazard of adverse cardiovascular outcomes. Finerenone reduced the incidence of hypokalaemia. Finerenone reduced the hazard of cardiovascular and arrhythmia outcomes irrespective of serum potassium subgroups.<\/jats:p>\n                    <jats:p>Clinical trials registration: FIDELIO-DKD and FIGARO-DKD are registered with ClinicalTrials.gov, numbers NCT02540993 and NCT02545049, respectively (funded by Bayer AG).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvae074","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T07:19:13Z","timestamp":1728285553000},"page":"10-19","source":"Crossref","is-referenced-by-count":7,"title":["Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone\u2014a FIDELITY analysis"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-275X","authenticated-orcid":false,"given":"Bertram","family":"Pitt","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Michigan School of Medicine , Ann Arbor, MI 48109 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Richard L. Roudebush VA Medical Center and Indiana University , Indianapolis, IN 46202 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3331-7314","authenticated-orcid":false,"given":"Stefan D","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK) of German Heart Center Charit\u00e9; German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin , Charit\u00e9pl. 1, 10117 Berlin ,","place":["Germany"]},{"name":"German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Copenhagen , Herlev 2730 ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen DK-2200 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Ruilope","sequence":"additional","affiliation":[{"name":"Cardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12 , Madrid 28041 ,","place":["Spain"]},{"name":"CIBER-CV, Hospital Universitario 12 de Octubre , Madrid 28041 ,","place":["Spain"]},{"name":"Faculty of Sport Sciences, European University of Madrid , Madrid 28670 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A","family":"Herzog","sequence":"additional","affiliation":[{"name":"Cardiology Division, Department of Internal Medicine, Hennepin Healthcare\/University of Minnesota , Minneapolis, MN 55404 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Greenberg","sequence":"additional","affiliation":[{"name":"University of California San Diego , La Jolla, CA 92037 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pecoits-Filho","sequence":"additional","affiliation":[{"name":"Arbor Research Collaborative for Health , Ann Arbor, MI 48108 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lambelet","sequence":"additional","affiliation":[{"name":"Chrestos Concept GmbH & Co. KG , Essen 45131 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lawatscheck","sequence":"additional","affiliation":[{"name":"Research and Development, Cardiology and Nephrology Clinical Development, Bayer AG , Berlin 13353 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Scalise","sequence":"additional","affiliation":[{"name":"Pharmaceutical Development, Bayer Hispania S.L., Division Pharmaceuticals , Barcelona 08970 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens , Athens 12462 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"2025030507022436600_bib1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.ackd.2017.06.004","article-title":"Hyperkalemia and hypokalemia in CKD: prevalence, risk factors, and clinical outcomes","volume":"24","author":"Gilligan","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"key":"2025030507022436600_bib2","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.mayocp.2020.06.014","article-title":"Clinical management of hyperkalemia","volume":"96","author":"Palmer","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2025030507022436600_bib3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000437151","article-title":"Serum potassium, end-stage renal disease and mortality in chronic kidney disease","volume":"41","author":"Nakhoul","year":"2015","journal-title":"Am J Nephrol"},{"key":"2025030507022436600_bib4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"2025030507022436600_bib5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","article-title":"Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology","volume":"4","author":"Rosano","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025030507022436600_bib6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cjca.2015.06.019","article-title":"The Canadian Cardiovascular Society heart failure companion: bridging guidelines to your practice","volume":"32","author":"Howlett","year":"2016","journal-title":"Can J Cardiol"},{"key":"2025030507022436600_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40620-019-00617-y","article-title":"Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology","volume":"32","author":"Bianchi","year":"2019","journal-title":"J Nephrol"},{"key":"2025030507022436600_bib8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10741-020-10039-9","article-title":"Serum potassium and heart failure: association, causation, and clinical implications","volume":"26","author":"Sfairopoulos","year":"2021","journal-title":"Heart Fail Rev"},{"key":"2025030507022436600_bib9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int"},{"key":"2025030507022436600_bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2215\/CJN.01020119","article-title":"Inadequate dietary potassium and progression of CKD","volume":"14","author":"DuBose","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025030507022436600_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/1744-9987.12753","article-title":"Association of low serum potassium levels and risk for all-cause mortality in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"23","author":"Zhang","year":"2019","journal-title":"Ther Apher Dial"},{"key":"2025030507022436600_bib12","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/HYPERTENSIONAHA.119.14063","article-title":"Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit","volume":"75","author":"Burrello","year":"2020","journal-title":"Hypertension"},{"key":"2025030507022436600_bib13","first-page":"573","article-title":"Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist","volume":"7","author":"Vardeny","year":"2014","journal-title":"Circ: Heart Fail"},{"key":"2025030507022436600_bib14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cardfail.2018.03.002","article-title":"Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial","volume":"24","author":"Desai","year":"2018","journal-title":"J Card Fail"},{"key":"2025030507022436600_bib15","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2025030507022436600_bib16","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.ekir.2021.05.027","article-title":"Mineralocorticoid receptor antagonism in chronic kidney disease","volume":"6","author":"Georgianos","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025030507022436600_bib17","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2025030507022436600_bib18","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2025030507022436600_bib19","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025030507022436600_bib20","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2025030507022436600_bib21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"key":"2025030507022436600_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and baseline characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am J Nephrol"},{"key":"2025030507022436600_bib23","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2215\/CJN.05850809","article-title":"Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study","volume":"5","author":"Korgaonkar","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025030507022436600_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2215\/CJN.01730215","article-title":"Association between serum potassium and outcomes in patients with reduced kidney function","volume":"11","author":"Luo","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025030507022436600_bib25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1681\/ASN.2008020159","article-title":"Timing of onset of CKD-related metabolic complications","volume":"20","author":"Moranne","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2025030507022436600_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"2025030507022436600_bib27","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Efficacy and safety of esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN)","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025030507022436600_bib28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"2025030507022436600_bib29","doi-asserted-by":"crossref","first-page":"114149","DOI":"10.1016\/j.biopha.2022.114149","article-title":"Mineralocorticoid receptor blockade improved gut microbiota dysbiosis by reducing gut sympathetic tone in spontaneously hypertensive rats","volume":"158","author":"Gonzalez-Correa","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2025030507022436600_bib30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.34067\/KID.0006762021","article-title":"Extrarenal effects of aldosterone on potassium homeostasis","volume":"3","author":"Palmer","year":"2022","journal-title":"Kidney360"},{"key":"2025030507022436600_bib31","doi-asserted-by":"crossref","first-page":"03000605221105163","DOI":"10.1177\/03000605221105163","article-title":"Local aldosterone synthesis in the large intestine of mouse: an ex vivo incubation study","volume":"50","author":"Pang","year":"2022","journal-title":"J Int Med Res"},{"key":"2025030507022436600_bib32","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"},{"key":"2025030507022436600_bib33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025030507022436600_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0000000000002216","article-title":"Renal damage in primary aldosteronism: a systematic review and meta-analysis","volume":"38","author":"Monticone","year":"2020","journal-title":"J Hypertens"},{"key":"2025030507022436600_bib35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev-med-042921-100438","article-title":"Primary aldosteronism and the role of mineralocorticoid receptor antagonists for the heart and kidneys","volume":"74","author":"Cohen","year":"2023","journal-title":"Annu Rev Med"},{"key":"2025030507022436600_bib36","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jss.2014.04.040","article-title":"Pretreatment with mineralocorticoid receptor blocker reduces intestinal injury induced by ischemia and reperfusion: involvement of inhibition of inflammatory response, oxidative stress, nuclear factor kappaB, and inducible nitric oxide synthase","volume":"191","author":"Ozacmak","year":"2014","journal-title":"J Surg Res"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae074\/60744807\/pvae074.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/1\/10\/60744807\/pvae074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/1\/10\/60744807\/pvae074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T02:02:42Z","timestamp":1741140162000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/1\/10\/7815899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10,8]]},"published-print":{"date-parts":[[2025,2,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae074","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,10,8]]}}}